Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Frontage Holdings (1521 HK)
Watchlist
58
Analysis
Health Care
•
China
Frontage Holdings Corporation operates as a biotechnology company. The Company offers clinical trials, bioequivalence studies, medical writing, and agrochemical services. Frontage Holdings serves customers in Hong Kong.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
WuXi XDC Cayman
•
08 Nov 2023 10:05
WuXi XDC IPO: Valuation Insights
Blue-chip cornerstones will purchase US$300 million of the offer. Our base-case DCF valuation is HK$22.84 per share, 12.8% above the midpoint of...
Arun George
Follow
545 Views
Share
bullish
•
WuXi XDC Cayman
•
06 Nov 2023 21:16
WuXi XDC IPO: Valuation First-Look
WuXi XDC is pre-marketing an HKEx IPO to raise US$500m. In this note, we present our forecasts and take the first look at the potential valuation...
Arun George
Follow
522 Views
Share
bearish
•
WuXi XDC Cayman
•
01 Nov 2023 18:21
WuXi XDC IPO: The Bear Case
The bear case rests on margins on a downward trend, large customer concentration, high related party transactions and volatile FCF generation.
Arun George
Follow
460 Views
Share
bullish
•
WuXi XDC Cayman
•
31 Oct 2023 16:21
WuXi XDC IPO: The Bull Case
The bull case rests on large addressable markets, market share gains, fast-paced revenue growth, strong revenue visibility, a solid balance sheet...
Arun George
Follow
494 Views
Share
bullish
•
Asymchem Laboratories Tianjin
•
01 Dec 2021 16:25
Asymchem Laboratories H Share Listing: Valuation Insights
The combination of a reasonable AH discount and relative valuation suggests the proposed H-share price range of HK$350-410 is attractive, in our view.
Arun George
Follow
272 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.32.0
x